Metalloproteinases and advanced glycation end products: Coupled navigation in atherosclerotic plaque pathophysiology?

Experimental and Clinical Endocrinology and Diabetes

Volumn 120, Issue 10, 2012, Pages 586-590

  Furfaro, A L ^a   Sanguineti, R ^a   Storace, D ^a   Monacelli, F ^a   Puzzo, A ^b   Pronzato, M A ^a   Odetti, P ^a   Traverso, N ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b GALLIERA HOSPITAL   (Italy)

Author keywords

atherosclerosis; diabetes; IL 1; MMP 2; pentosidine; TIMP 3

Indexed keywords

GELATINASE A; INTERLEUKIN 1; PENTOSIDINE; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CLINICAL ARTICLE; DIABETES MELLITUS; EX VIVO STUDY; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HYPERTENSION; INFLAMMATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR;

AGED; ARGININE; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CAROTID ARTERY, INTERNAL; CAROTID STENOSIS; DIABETIC ANGIOPATHIES; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1ALPHA; ITALY; LYSINE; MATRIX METALLOPROTEINASE 2; METALLOPROTEASES; PLAQUE, ATHEROSCLEROTIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 84870300659     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0032-1323739     Document Type: Article

References (48)

1. Pamukcu B., Lip G. Y., Devitt A. et al. The role of monocytes in atherosclerotic coronary artery disease. Ann Med: 2010; 42 394 403
2. Carter A. M. Inflammation, thrombosis and acute coronary syndromes. Diab Vasc Dis Res: 2005; 2 113 121 (Pubitemid 41695169)
3. Falk E., Shah P. K., Fuster V. Coronary plaque disruption. Circulation: 1995; 92 657 671
4. Page-McCaw A., Ewald A. J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol: 2007; 8 221 233
5. Kadoglou N. P., Daskalopoulou S. S., Perrea D. et al. Matrix metalloproteinases and diabetic vascular complications. Angiology: 2005; 56 173 189 (Pubitemid 40404472)
6. Cullen P., Baetta R., Bellosta S. et al. Rupture of the atherosclerotic plaque: does a good animal model exist? Arterioscler Thromb Vasc Biol: 2003; 23 535 542 (Pubitemid 36438064)
7. Newby A. C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev: 2005; 85 1 31 (Pubitemid 40171256)
8. Henney A. M., Wakeley P. R., Davies M. J. et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA: 1991; 88 8154 8158 (Pubitemid 21915315)
9. Galis Z. S., Sukhova G. K., Lark M. W. et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest: 1994; 94 2493 2503 (Pubitemid 24379627)
10. Nikkari S. T., Geary R. L., Hatsukami T. et al. Expression of collagen, interstitial collagenase, and tissue inhibitor of metalloproteinases-1 in restenosis after carotid endarterectomy. Am J Pathol: 1996; 148 777 783 (Pubitemid 126660670)
11. Li Z., Li L., Zielke H. R. et al. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol: 1996; 148 121 128 (Pubitemid 26019650)
12. Brown D. L., Hibbs M. S., Kearney M. et al. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation: 1995; 91 2125 2131
13. Schonbeck U., Mach F., Sukhova G. K. et al. Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med: 1999; 189 843 853 (Pubitemid 29189689)
14. Pauly R. R., Passaniti A., Bilato C. et al. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res: 1994; 75 41 54 (Pubitemid 24187734)
15. Rajavashisth T. B., Xu X. P., Jovinge S. et al. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation: 1999; 99 3103 3109 (Pubitemid 29289074)
16. Fabunmi R. P., Sukhova G. K., Sugiyama S. et al. Expression of tissue inhibitor of metalloproteinases-3 in human atheroma and regulation in lesion-associated cells: a potential protective mechanism in plaque stability. Circ Res: 1998; 83 270 278 (Pubitemid 28371316)
17. Raffetto J. D., Khalil R. A. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol: 2008; 75 346 359 (Pubitemid 350298459)
18. Higashikata T., Yamagishi M., Higashi T. et al. Altered expression balance of matrix metalloproteinases and their inhibitors in human carotid plaque disruption: results of quantitative tissue analysis using real-time RT-PCR method. Atherosclerosis: 2006; 185 165 172 (Pubitemid 43117564)
19. Pedersen S. F., Graebe M., Fisker Hag A. M. et al. Gene expression and 18FDG uptake in atherosclerotic carotid plaques. Nucl Med Commun: 2010; 31 423 429
20. Murillo C. A., Woodside K. J., Guo Q. et al. Integrin and matrix metalloproteinase expression in human carotid plaque. J Surg Res: 2009; 155 157 164
21. Fiotti N., Altamura N., Orlando C. et al. Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI. Int J Cardiol: 2008; 127 350 357 (Pubitemid 351885084)
22. Arno G., Kaski J. C., Smith D. A. et al. Matrix metalloproteinase-9 expression is associated with the presence of Chlamydia pneumoniae in human coronary atherosclerotic plaques. Heart: 2005; 91 521 525 (Pubitemid 40432789)
23. Baynes J. W., Thorpe S. R. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med: 2000; 28 1708 1716 (Pubitemid 30628657)
24. Sims T. J., Rasmussen L. M., Oxlund H. et al. The role of glycation cross-links in diabetic vascular stiffening. Diabetologia: 1996; 39 946 951 (Pubitemid 26249114)
25. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis: 2008; 196 9 21
26. Schmidt A. M., Hori O., Chen J. X. et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest: 1995; 96 1395 1403
27. Baynes J. W. The role of AGEs in aging: causation or correlation. Exp Gerontol: 2001; 36 1527 1537 (Pubitemid 32771329)
28. Meng J., Sakata N., Takebayashi S. et al. Glycoxidation in aortic collagen from STZ-induced diabetic rats and its relevance to vascular damage. Atherosclerosis: 1998; 136 355 365 (Pubitemid 28133425)
29. Hoshino H., Takahashi M., Kushida K. et al. Quantitation of the crosslinks, pyridinoline, deoxypyridinoline and pentosidine, in human aorta with dystrophic calcification. Atherosclerosis: 1995; 112 39 46
30. Imanaga Y., Sakata N., Takebayashi S. et al. In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human atherosclerotic plaques. Atherosclerosis: 2000; 150 343 355 (Pubitemid 30336546)
31. Yan S. F., Ramasamy R., Schmidt A. M. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab: 2008; 4 285 293 (Pubitemid 351571138)
32. Okano Y., Masaki H., Sakurai H. Dysfunction of dermal fibroblasts induced by advanced glycation end-products (AGEs) and the contribution of a nonspecific interaction with cell membrane and AGEs. J Dermatol Sci: 2002; 29 171 180 (Pubitemid 35375272)
33. Molinari J., Ruszova E., Velebny V. et al. Effect of advanced glycation endproducts on gene expression profiles of human dermal fibroblasts. Biogerontology: 2008; 9 177 182
34. Rittie L., Berton A., Monboisse J. C. et al. Decreased contraction of glycated collagen lattices coincides with impaired matrix metalloproteinase production. Biochem Biophys Res Commun: 1999; 264 488 492 (Pubitemid 29516113)
35. Cipollone F., Iezzi A., Fazia M. et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation: 2003; 108 1070 1077 (Pubitemid 37071516)
36. Ishibashi T., Kawaguchi M., Sugimoto K. et al. Advanced glycation end product-mediated matrix metallo-proteinase-9 and apoptosis via renin-angiotensin system in type 2 diabetes. J Atheroscler Thromb: 2010; 17 578 589
37. Hammoud L., Lu X., Lei M. et al. Deficiency in TIMP-3 increases cardiac rupture and mortality post-myocardial infarction via EGFR signaling: beneficial effects of cetuximab. Basic Res Cardiol: 2011
38. Odetti P., Fogarty J., Sell D. R. et al. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes: 1992; 41 153 159
39. Stegemann H., Stalder K. Determination of hydroxyproline. Clin Chim Acta: 1967; 18 267 273
40. Colgrave M. L., Allingham P. G., Jones A. Hydroxyproline quantification for the estimation of collagen in tissue using multiple reaction monitoring mass spectrometry. J Chromatogr A: 2008; 1212 150 153
41. Michel J. B., Virmani R., Arbustini E. et al. Intraplaque haemorrhages as the trigger of plaque vulnerability. Eur Heart J: 2011; 32 1977 1985 1985a, 1985b, 1985c
42. Uemura S., Matsushita H., Li W. et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res: 2001; 88 1291 1298 (Pubitemid 32587846)
43. Marfella R., DAmico M., Esposito K. et al. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes: 2006; 55 622 632 (Pubitemid 43343218)
44. Zhou Y. J., Wang J. H., Li L. et al. Expanding expression of the 5-lipoxygenase/leukotriene B4 pathway in atherosclerotic lesions of diabetic patients promotes plaque instability. Biochem Biophys Res Commun: 2007; 363 30 36 (Pubitemid 47430091)
45. Tsilibary E. C. Microvascular basement membranes in diabetes mellitus. J Pathol: 2003; 200 537 546 (Pubitemid 36818254)
46. Chung A. W., Luo H., Tejerina T. et al. Enhanced cell cycle entry and mitogen-activated protein kinase-signaling and downregulation of matrix metalloproteinase-1 and -3 in human diabetic arterial vasculature. Atherosclerosis: 2007; 195 e1 e8 (Pubitemid 47561953)
47. Basu P., Sen U., Tyagi N. et al. Blood flow interplays with elastin: collagen and MMP: TIMP ratios to maintain healthy vascular structure and function. Vasc Health Risk Manag. 2010; 6 215 228
48. DeGroot J., Verzijl N., Wenting-Van Wijk M. J. et al. Age-related decrease in susceptibility of human articular cartilage to matrix metalloproteinase-mediated degradation: the role of advanced glycation end products. Arthritis Rheum: 2001; 44 2562 2571 (Pubitemid 33049335)